1. From the Cardiovascular Medicine Unit, National Heart & Lung Institute, Faculty of Medicine, Imperial College London, Hammersmith Hospital, London, United Kingdom; and DG Thrombotic/Degenerative Joint Diseases, Aventis Pharma Deutschland, Frankfurt am Main, Germany.